BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1571 related articles for article (PubMed ID: 18991189)

  • 1. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in portuguese SLE patients: an outcome measure independent of disease activity and cumulative damage.
    Duarte C; Abreu P; Couto M; Vaz C; Malcata A; Inês L
    Acta Reumatol Port; 2010; 35(1):30-5. PubMed ID: 20518146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of menopause on disease activity in systemic lupus erythematosus.
    Urowitz MB; Ibañez D; Jerome D; Gladman DD
    J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
    Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
    J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus.
    Stoll T; Gordon C; Seifert B; Richardson K; Malik J; Bacon PA; Isenberg DA
    J Rheumatol; 1997 Aug; 24(8):1608-14. PubMed ID: 9263159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associates of health status in patients with systemic lupus erythematosus.
    Sutcliffe N; Clarke AE; Levinton C; Frost C; Gordon C; Isenberg DA
    J Rheumatol; 1999 Nov; 26(11):2352-6. PubMed ID: 10555890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
    Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
    J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibromyalgia is a major contributor to quality of life in lupus.
    Gladman DD; Urowitz MB; Gough J; MacKinnon A
    J Rheumatol; 1997 Nov; 24(11):2145-8. PubMed ID: 9375874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity.
    Neville C; Clarke AE; Joseph L; Belisle P; Ferland D; Fortin PR
    J Rheumatol; 2000 Mar; 27(3):675-9. PubMed ID: 10743807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in systemic lupus erythematosus and its association with disease and work disability.
    Almehed K; Carlsten H; Forsblad-d'Elia H
    Scand J Rheumatol; 2010; 39(1):58-62. PubMed ID: 20132072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?
    Jolly M
    J Rheumatol; 2005 Sep; 32(9):1706-8. PubMed ID: 16142864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus.
    Nived O; Jönsen A; Bengtsson AA; Bengtsson C; Sturfelt G
    J Rheumatol; 2002 Jul; 29(7):1398-400. PubMed ID: 12136895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices.
    Moore AD; Clarke AE; Danoff DS; Joseph L; Bélisle P; Neville C; Fortin PR
    J Rheumatol; 1999 Jun; 26(6):1285-90. PubMed ID: 10381044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality.
    Becker-Merok A; Nossent HC
    J Rheumatol; 2006 Aug; 33(8):1570-7. PubMed ID: 16845708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected].
    Chaiamnuay S; Bertoli AM; Fernández M; Apte M; Vilá LM; Reveille JD; Alarcón GS;
    J Clin Rheumatol; 2007 Jun; 13(3):128-33. PubMed ID: 17551377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years.
    Gilboe IM; Kvien TK; Husby G
    J Rheumatol; 2001 Feb; 28(2):266-74. PubMed ID: 11246660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease.
    Vu TV; Escalante A
    J Rheumatol; 1999 Dec; 26(12):2595-601. PubMed ID: 10606368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between health-related quality of life and SLE activity and damage in children over time.
    Moorthy LN; Peterson MG; Hassett AL; Baratelli M; Chalom EC; Hashkes PJ; Hong S; Reiff A; Lehman TJ
    Lupus; 2009 Jun; 18(7):622-9. PubMed ID: 19433463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cigarette smoking and cutaneous damage in systemic lupus erythematosus.
    Turchin I; Bernatsky S; Clarke AE; St-Pierre Y; Pineau CA
    J Rheumatol; 2009 Dec; 36(12):2691-3. PubMed ID: 19884279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.